Insider Selling: LivaNova (NASDAQ:LIVN) CFO Sells $227,275.00 in Stock

LivaNova PLC (NASDAQ:LIVN) CFO Alex Shvartsburg sold 2,500 shares of LivaNova stock in a transaction dated Thursday, November 12th. The stock was sold at an average price of $90.91, for a total value of $227,275.00. Following the completion of the transaction, the chief financial officer directly owned 42,147 shares in the company, valued at $3,831,583.77. This represents a 5.60% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

LivaNova Trading Up 1.2%

NASDAQ LIVN traded up $1.12 on Friday, hitting $91.32. 742,276 shares of the company were exchanged, compared to its average volume of 743,907. The company has a debt-to-equity ratio of 0.22, a current ratio of 1.46 and a quick ratio of 1.22. LivaNova PLC has a twelve month low of $52.37 and a twelve month high of $99.38. The firm has a market capitalization of $5.03 billion, a P/E ratio of 30.44 and a beta of 0.91. The company’s 50 day moving average price is $80.12 and its 200-day moving average price is $74.09.

LivaNova (NASDAQ:LIVN) last announced its earnings results on Wednesday, November 4th. The company reported $1.23 EPS for the quarter, topping the consensus estimate of $1.06 by $0.17. The company had revenue of $393.15 million during the quarter, compared to analysts’ expectations of $381.13 million. LivaNova had a net margin of 13.01% and a return on equity of 16.10%. The business’s revenue for the quarter was up 9.9% on a year-over-year basis. During the same period last year, the company posted $1.11 earnings per share. Analysts predict that LivaNova PLC will post 3.76 earnings per share for the current fiscal year.

Institutional Trading of LivaNova

Institutional investors have recently made changes to their positions in the stock. Allworth Financial LP increased its stake in LivaNova by 93.5% in the 2nd quarter. Allworth Financial LP now owns 298 shares of the company’s stock valued at $25,000 after buying an additional 144 shares during the period. Root Financial Partners LLC acquired a new stake in shares of LivaNova during the 3rd quarter valued at $32,000. Farther Finance Advisors LLC boosted its stake in shares of LivaNova by 59.7% during the 3rd quarter. Farther Finance Advisors LLC now owns 452 shares of the company’s stock valued at $35,000 after buying an additional 169 shares during the period. Public Employees Retirement System of Ohio purchased a new position in shares of LivaNova during the 2nd quarter valued at $37,000. Finally, Bessemer Group Inc. grew its holdings in shares of LivaNova by 27.8% during the 3rd quarter. Bessemer Group Inc. now owns 520 shares of the company’s stock valued at $40,000 after acquiring an additional 113 shares in the last quarter. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

LIVN has been the subject of several research analyst reports. Wall Street Zen downgraded shares of LivaNova from a “strong-buy” rating to a “buy” rating in a research report on Saturday, November 7th. Barclays lifted their price objective on shares of LivaNova from $105.00 to $120.00 and gave the stock an “overweight” rating in a research report on Monday. Zacks Research downgraded shares of LivaNova from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, August 19th. Raymond James Financial set a $120.00 target price on LivaNova in a report on Wednesday, November 4th. Finally, Robert W. Baird raised their target price on LivaNova from $95.00 to $111.00 and gave the stock an “outperform” rating in a research report on Thursday, November 5th. Nine analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to MarketBeat.com, LivaNova presently has an average rating of “Moderate Buy” and an average price target of $101.22.

LivaNova Company Profile

LivaNova plc is a global medical technology company that develops and manufactures products for cardiovascular care and neuromodulation. The company was formed in 2015 through the combination of Cyberonics and Sorin Group. In neuromodulation, LivaNova’s VNS Therapy system delivers vagus nerve stimulation and is used as an adjunctive treatment for certain people with drug-resistant epilepsy and treatment-resistant depression. Its cardiovascular products support cardiac surgery and include heart-lung machines, oxygenators and related perfusion equipment.